BLPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BLPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bellerophon Therapeutics's total inventories for the quarter that ended in Sep. 2023 was $0.00 Mil. Bellerophon Therapeutics's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Sep. 2023 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Bellerophon Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $0.26.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Bellerophon Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellerophon Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Bellerophon Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Bellerophon Therapeutics (OTCPK:BLPH) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Bellerophon Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is
Net-Net Working Capital Per Share (Q: Sep. 2023 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (4.382 | + | 0.75 * 0 | + | 0.5 * 0 | - | 1.256 |
- | 0 | - | 0) | / | 12.2326 | ||
= | 0.26 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Bellerophon Therapeutics's Days Inventory for the three months ended in Sep. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2023 ) | / | Cost of Goods Sold (Q: Sep. 2023 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Bellerophon Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2023 ) | / | Average Total Inventories (Q: Sep. 2023 ) |
= | 0 | / | 0 | |
= | N/A |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bellerophon Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Sep. 2023 ) | / | Revenue (Q: Sep. 2023 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Bellerophon Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Puissance Life Science Opportunities Fund Vi | 10 percent owner | 950 THIRD AVENUE, FL 25, NEW YORK NY 10022 |
Naseem Amin | director | 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827 |
Mary Ann Cloyd | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Theodore T Wang | director | C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Scott P Bruder | director | C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827 |
Crispin Teufel | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Puissance Capital Fund (gp) Llc | 10 percent owner | 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Parag Suresh Shah | officer: VP of Business Operations | C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059 |
Martin Dekker | officer: See Remarks | 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827 |
Peter Fernandes | officer: See Remarks | PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827 |
Bobae Kim | officer: VP Reg. Affairs & Quality | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Nicholas Laccona | officer: Controller, (PFO & PAO) | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Steven B Klinsky | 10 percent owner | C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019 |
New Mountain Capital, L.l.c. | 10 percent owner | 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019 |
New Mountain Investments Ii, Llc | 10 percent owner | 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By Marketwired Marketwired • 09-07-2021
By GuruFocusNews GuruFocusNews • 05-22-2022
By PRNewswire PRNewswire • 12-17-2021
By sperokesalga sperokesalga • 05-11-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 05-12-2022
By sperokesalga sperokesalga • 02-09-2023
By Don Li2 Don Li2 • 11-15-2021
By GuruFocusNews GuruFocusNews • 07-01-2022
By GuruFocusNews GuruFocusNews • 12-17-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.